Glycoprotein IIb/IIIa receptors are the most common receptor subtypes on the platelet surface. During vessel injury, the sub-endothelial layer is exposed so that platelets adhere to sub-endothelial collagen via la/Ila receptor and to von Willebrand factor via glycoprotein Ib receptor. Adherent platelets are activated by ADP, 5-HT, TXA2 etc which result in the conformational change of platelets, thereby activating nearly 80,000 GP IIb/IIIa receptors on platelet surface. These activated receptors bind fibrinogen to fascilate the formation of a platelet plug. 1, 2 Currently, there are three GP IIb/IIIa inhibitors available for clinical use, Abciximab, Ebtifibatide and Tirofabin. This review article will highlight on the recent trends for the use of GP IIb/IlIa inhibitors in different clinical settings. First of all, the use of GP IIb/IIIa inhibitors is divided into two large groups, during PCI and during. Conservative management. During PCT, its use is again categorized into three subgroups: PCI for stable CAD, in the setting of Non-ST segment elevation acute coronary syndrome(NSTE-ACS, that is, unstable angina and Non-ST elevation MI) and, ST segment elevation MI (STEMI). Similarly, during conservative management, its use is discussed in two subgroups: in the setting of NSTE-ACS and in STEMI. This article will also discuss on specific situations like diabetics patients undergoing PCI and high risk NSTE-ACS.
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The result of PCI in diabetic patients is not as good as non-diabetic patients. This is perhaps due to enhanced platelet activation, aggregability and greater expression of GP IIb/IIla receptors. So, there might be hypothesis that diabetic patients need to be managed more aggressively using GP IIb/IlIa inhibitors during PCI. The retrospective analysis of diabetic subgroups in EPISTENT study showed that there is prognostic benefit of Abciximab in diabetic groups. 36 But as stated earlier this study had mixed population of stable and unstable CAD and the subgroup analysis was retrospective not prospective. This issue has been highlighted in ISAR-SWEET trial. 7 ISAR-SWEET (is abciximab Superior Way to Eliminate Thrombotic risk in diubetes) was a prospective trial enrolling diabetic patients undergoing elective PCI with pre-treatment by 600 mg clopidogrel. The result showed that Abciximab did not provide extra benefit in terms of death and MI. Thus, whether Abciximab should be routinely used in all diabetic patients undergoing elective PCI is not yet proved.
In comparision to Abciximab, the benefits were less marked with the use of small molecules GP IIb/IIIa inhibitors (Ebtifibatide and tirofabin) as observed in IMPACT-II trial 9 with Ebtifibatide and RESTORE trial 12 with Tirofiban.
B. Role during PCT for NSTE-ACS (Unstable angina and NSTEMI)
Although benefit of GP IIb/IIIa inhibitors is seen across all groups, this benefit is more prominent in ACS patients. There are several trials showing the usefulness of GP IIb/IIla inhibitors in patients with stable angina or NSTE-ACS. Among three GP IIb/IIIa inhibitors, Abciximab has been extensively studied as in EPIC, EPILOG, EPISTENT and CAPTURE trial 8 . The role of ebtifibatide has been studied in IMPACT-II and ESPIRIT 10,11 trials and that of Tirofiban in RESTORE 12 and TARGET trials, 13 There is prominent role of Abciximab during PCI in ACS patients as shown in EPIC, EPILOG and EPISTENT trial. But it should be noted that these trial comprised the mixed population of stable and unstable CAD, Whether the small molecule GP IIb/IIIa was also useful during PCI in NSTE-ACS was studied in IMPACT-II 9 and ESPIRIT 10,11 trials for Ebtifibatide and in RESTORE 12 and TARGET 13 trials for Tirofiban. In RESTORE trial 12 (Randomized Efficacy Study of Tirofiban for Outcomes and Restenosis), the composite end point of death, MI, urgent TVR or bailout treatment was 12.2% in placebo vs 10.3% in Tirofiban group, which was not statistically significant. Further, Tirofiban was directly compared with Abciximab in TARGET trial 13 (Do Tirofiban And Reopro Give similar Efficacy). It was found that Abciximab was superior to Tirofiban in reducing composite end point of death, MI or TVR at 30 days in the subgroup of patients with ACS (6.35 vs 9.3 %, p=0.002). The TENACITY trial will study a higher dose of Tirofiban than in TARGET and compare it head to head with Abciximab.
In conclusion, when PCI is planned, Abciximab is the best tested drug, as shown in EPIC, EPILOG, EPISTENT and CAPTURE trials. In such setting, high dose Ebtifibatide is also better alternative as shown in ESPIRIT trial but the role of Tirofiban is still controversial.
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Despite successful revascularization in primary PCI, there might be sub-optimal microvascular reperfusion due to distal embolization with platelet aggregrgates which necessitate the use of potent anuplitelet agent. The role of GP IIb/Illa inhibitors, especially Abciximab has been well studied in the setting of primary PCI. Abciximab has been studied in five randomized trials 14, 18 (RAPPORT, ISAR 
